{"aliases":[{"type":"CodeName","name":"C225"},{"type":"Synonym","name":"C225 monoclonal antibody"},{"type":"Abbreviation","name":"MOAB C225"},{"type":"Synonym","name":"monoclonal antibody C225"},{"type":"CodeName","name":"IMC-C225"},{"type":"Synonym","name":"Anti-EGFR Monoclonal Antibody"},{"type":"Synonym","name":"Anti-Epidermal Growth Factor Receptor Monoclonal Antibody"},{"type":"USBrandName","name":"Erbitux"},{"type":"Synonym","name":"Immunoglobulin G1, anti-(human epidermal growth factor receptor) (human-mouse monoclonal C225 gamma1-chain), disulfide with human-mouse monoclonal C225 kappa-chain, dimer"},{"type":"Abbreviation","name":"Chimeric MoAb C225"},{"type":"Synonym","name":"Chimeric Anti-EGFR Monoclonal Antibody"},{"type":"Synonym","name":"Chimeric Monoclonal Antibody C225"},{"type":"Synonym","name":"cetuximab biosimilar CMAB009"},{"type":"Synonym","name":"cetuximab biosimilar KL 140"},{"type":"Synonym","name":"cetuximab biosimilar CDP-1"},{"type":"INDCode","name":"3610"},{"type":"INDCode","name":"11460"},{"type":"NSCNumber","name":"714692"},{"type":"CASRegistryName","name":"205923-56-4"}],"definition":{"html":"A recombinant, chimeric monoclonal antibody directed against the epidermal growth factor (EGFR) with antineoplastic activity. Cetuximab binds to the extracellular domain of the EGFR, thereby preventing the activation and subsequent dimerization of the receptor; the decrease in receptor activation and dimerization may result in an inhibition in signal transduction and anti-proliferative effects. This agent may inhibit EGFR-dependent primary tumor growth and metastasis. EGFR is overexpressed on the cell surfaces of various solid tumors.","text":"A recombinant, chimeric monoclonal antibody directed against the epidermal growth factor (EGFR) with antineoplastic activity. Cetuximab binds to the extracellular domain of the EGFR, thereby preventing the activation and subsequent dimerization of the receptor; the decrease in receptor activation and dimerization may result in an inhibition in signal transduction and anti-proliferative effects. This agent may inhibit EGFR-dependent primary tumor growth and metastasis. EGFR is overexpressed on the cell surfaces of various solid tumors."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/cetuximab","text":"Cetuximab"},"nciConceptId":"C1723","nciConceptName":"Cetuximab","termId":42384,"name":"cetuximab","firstLetter":"c","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"cetuximab"}